These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 15914874)
1. Daptomycin: we'll make more, they'll make more. Barber GR Am J Health Syst Pharm; 2005 Jun; 62(11):1143. PubMed ID: 15914874 [No Abstract] [Full Text] [Related]
2. Development of High-Grade Daptomycin Resistance in a Patient Being Treated for Corynebacterium striatum Infection. Ajmal S; Saleh OA; Beam E Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483949 [No Abstract] [Full Text] [Related]
3. When less is more: high-dose, short duration regimens and antibiotic resistance. Stein RA Int J Clin Pract; 2008 Sep; 62(9):1304-5. PubMed ID: 18793374 [No Abstract] [Full Text] [Related]
4. High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides. Lichterfeld M; Ferraro MJ; Davis BT Int J Antimicrob Agents; 2010 Jan; 35(1):96. PubMed ID: 19896341 [No Abstract] [Full Text] [Related]
5. Antimicrobial resistance: a priority for global health action. Chioro A; Coll-Seck AM; Høie B; Moeloek N; Motsoaledi A; Rajatanavin R; Touraine M Bull World Health Organ; 2015 Jul; 93(7):439. PubMed ID: 26170498 [No Abstract] [Full Text] [Related]
10. Antimicrobial Resistance: An Antimicrobial/Diagnostic Stewardship and Infection Prevention Approach. Septimus EJ Med Clin North Am; 2018 Sep; 102(5):819-829. PubMed ID: 30126573 [TBL] [Abstract][Full Text] [Related]
11. Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis. Pericàs JM; García-de-la-Mària C; Brunet M; Armero Y; García-González J; Casals G; Almela M; Quintana E; Falces C; Ninot S; Fuster D; Llopis J; Marco F; Moreno A; Miró JM; J Antimicrob Chemother; 2017 Jun; 72(6):1714-1722. PubMed ID: 28204495 [TBL] [Abstract][Full Text] [Related]
12. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Jacqueline C; Amador G; Batard E; Le Mabecque V; Miègeville AF; Biek D; Caillon J; Potel G J Antimicrob Chemother; 2011 Apr; 66(4):863-6. PubMed ID: 21393213 [TBL] [Abstract][Full Text] [Related]
16. Multidrug-resistant Corynebacterium striatum endocarditis successfully treated with daptomycin. Fernández Guerrero ML; Molins A; Rey M; Romero J; Gadea I Int J Antimicrob Agents; 2012 Oct; 40(4):373-4. PubMed ID: 22817918 [No Abstract] [Full Text] [Related]
17. Daptomycin in the treatment of prosthetic joint infection by Enterococcus faecalis: safety and efficacy of high-dose and prolonged therapy. Yuste JR; Quesada M; Díaz-Rada P; Del Pozo JL Int J Infect Dis; 2014 Oct; 27():65-6. PubMed ID: 25192907 [TBL] [Abstract][Full Text] [Related]
18. Daptomycin: a comparison of two intravenous formulations. Frankenfeld C; Mittal S; Melendez Y; Mendez-Vigo L; Lamp KC; Keller KN; Bertolami SR Drug Des Devel Ther; 2018; 12():1953-1958. PubMed ID: 29988771 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. Rose WE; Rybak MJ; Kaatz GW J Antimicrob Chemother; 2007 Aug; 60(2):334-40. PubMed ID: 17540670 [TBL] [Abstract][Full Text] [Related]
20. Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? Falcone M; Russo A; Cassetta MI; Lappa A; Tritapepe L; d'Ettorre G; Fallani S; Novelli A; Venditti M J Infect Chemother; 2013 Aug; 19(4):732-9. PubMed ID: 23361566 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]